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Abstract
 
Strategies to enhance the immunogenicity of tumors are urgently needed. Although vaccina-
tion with irradiated dying lymphoma cells recruits a tumor-specific immune response, its effi-
ciency as immunogen is poor. Annexin V (AxV) binds with high affinity to phosphatidylserine
on the surface of apoptotic and necrotic cells and thereby impairs their uptake by macrophages.
Here, we report that AxV preferentially targets irradiated lymphoma cells to CD8
 
 
 
 dendritic
cells for in vivo clearance, elicits the release of proinflammatory cytokines and dramatically en-
hances the protection elicited against the tumor. The response was endowed with both memory,
because protected animals rejected living lymphoma cells after 72 d, and specificity, because
vaccinated animals failed to reject unrelated neoplasms. Finally, AxV–coupled irradiated cells
induced the regression of growing tumors. These data indicate that endogenous adjuvants that
bind to dying tumor cells can be exploited to target tumors for immune rejection.
Key words: apoptosis • phagocytosis • cancer • adjuvants • dendritic cells
 
Introduction
 
The swift recognition and the phagocytosis of apoptotic
cells are the object of intense investigation (1, 2). However,
the fate of the antigens they contain and the constrains lim-
iting their immunogenicity in vivo are scarcely understood.
Apoptotic cell antigens enter the MHC class I pathway of
the phagocyte via the cytosol and become available for rec-
ognition by MHC-restricted cytotoxic T lymphocytes. After
engulfment of apoptotic cells, monocytes/macrophages (M
 
 
 
)
release antiinflammatory cytokines, such as IL-10 and
TGF-
 
 
 
 (2). DCs that phagocytosed virus-infected apoptotic
cells productively activate (cross-prime; reference 3) virus-
specific cytotoxic T lymphocytes (4). DCs are unusually effi-
cient in processing internalized dying cells for presentation
to MHC class I– and class II–restricted T lymphocytes. Ac-
cordingly, DCs that internalized dying tumor cells effi-
ciently cross-activate tumor-specific T cells, both in vitro
and in vivo (5). The presence of M
 
 
 
, which release factors
that prevent the maturation and the function of DCs, abro-
gates the cross-priming of T cells by phagocytosing DCs (4).
The in vivo immunogenicity of the highly tumorigenic
Rauscher virus–induced H-2
 
b
 
 RMA lymphoma dramati-
cally abates after apoptosis induction (6). The efficacy of
RMA lymphoma cells as vaccines was partially rescued in
IL-10 knockout mice (6). Moreover, annexin V (AxV)
hindering the recognition of exposed phosphatidylserine
(PS) restored the ability of dying xenogeneic cells to evoke
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antibody responses in vivo (7). Altogether, the results sug-
gest that dying cells administered in vivo cause the secre-
tion of factors that in turn restrict their immunogenicity
(immunosuppressive clearance).
It is well established that PS serves as a recognition signal
for the clearance of apoptotic cells. The redistribution of
PS both on phagocyte and prey is involved (8). A well-
characterized receptor mediates the PS-dependent uptake
of apoptotic cells (PS receptor; reference 9), engaging a sig-
naling pathway crucial for the rearrangement of phago-
cytes’ actin-based cytoskeleton with eventual engulfment
of the corpse. The activation of this receptor induces the
release of immunosuppressive cytokines (9). Accordingly,
animals lacking PS receptor accumulate uncleared apop-
totic cells at the periphery and targeted mice develop tissue
inflammation (1, 10, 11). AxV, which binds to exposed PS
residues in vitro and in vivo, inhibits apoptotic cell uptake
by M
 
 
 
 most likely through interference with the availabil-
ity of PS for recognition (8, 12–14).
We hypothesized that the availability of AxV at the site
of dying tumor cell clearance disrupts their PS-dependent
recognition and, therefore, abrogates the immunosuppres-
sive clearance. Indeed, addition of AxV strikingly height-
ened the immune response irradiated RMA cells elicit in
vivo, including rejection of growing tumors.
 
Materials and Methods
 
Preparation of AxV.
 
We cloned and isolated chicken AxV
used in our studies as described previously (15). In brief, AxV was
synthesized in 
 
Escherichia coli
 
 upon induction with isopropyl thio-
 
d
 
-galactoside and purified with a protocol based on the ability of
AxV to interact reversibly with PS-containing liposomes in the
presence of calcium. Human recombinant AxV was provided by
Boehringer Ingelheim. The coding region of the mouse AxV
cDNA (Genbank/EMBL/DDBJ: accession no. MMU29396) was
amplified from corresponding cDNA clones (IMAGE; RZPD)
by PCR and inserted in the vector pQE60 for recombinant ex-
pression in 
 
E. coli
 
 and purified as described before (15). Prepara-
tions were dialyzed against 50 mM Tris, 1 mM EGTA, pH 7.4,
and purified on Poros HQ20 anion-exchange (Applied Biosys-
tems) and on detoxi-gel affinity Pak (Pierce Chemical Co.) col-
umns. The contamination with endotoxin was 
 
 
 
5 EU/ml.
 
Mice and Tumors.
 
C57BL/6 female mice, 6–8-wk-old (Charles
River Laboratories), were housed in a pathogen-free animal facil-
ity and treated in accordance with the European Community
guidelines. The Institutional Animal Care and Use Committee of
the H. San Raffaele Scientific Institute gave approval for the ani-
mal experiments. The H-2
 
b
 
 RMA lymphoma cell line was pro-
vided by V. Cerundolo (John Radcliff Hospital, Oxford, En-
gland, UK). The H-2
 
b
 
 B16F1 melanoma cell line was purchased
from American Type Culture Collection. Cell lines were rou-
tinely tested for mycoplasma infection.
 
Cell Death.
 
We irradiated RMA cells using an UV source as
described previously, treated them with mitomycin C (50 
 
 
 
g/ml
for 1 h at 37
 
 
 
C), and washed them extensively (16). We used
FITC-labeled AxV (provided by V. Occhiena, Bender MedSys-
tems, Torino, Italy) to assess the externalization of PS and pro-
pidium iodide to evaluate plasma membrane integrity. Cells were
analyzed at 0, 3, 9, and 16 h after irradiation, in the presence or
absence of divalent cations. The specificity of the binding of AxV
was also evaluated by treating irradiated cells with increasing
amounts (range tested 1–500 
 
 
 
g/ml) of unlabeled AxV or BSA
and assessing the residual binding of FITC-AxV (5 
 
 
 
g/ml) by
flow cytometry. We analyzed samples with a FACScan apparatus
(Becton Dickinson). When indicated, chicken albumin (Sigma-
Aldrich) was coupled to the membrane of apoptotic tumor cells,
using the three-step approach described previously (17, 18): apop-
totic cells were biotinylated before incubation with 10 
 
 
 
g/ml
streptavidin (Biospa) in PBS containing 2% FCS (PBS/FCS) (30
min at 4
 
 
 
C), followed by 100 
 
 
 
g/ml biotin–chicken albumin (45
min at 4
 
 
 
C).
 
Dendritic Cells and M
 
 
 
.
 
DCs were derived from bone marrow
precursors propagated for 7 d in complete medium containing
1,000 U/ml recombinant murine GM-CSF and 5 ng/ml recombi-
nant murine IL-4 (BD Biosciences). M
 
 
 
 were isolated from
thioglycollate-elicited peritoneal lavages by plastic adherence (9).
 
In Vitro Clearance of Irradiated Cells.
 
Biotinylated irradiated
RMA cells were incubated with 
 
125
 
I-labeled streptavidin (Amer-
sham Biosciences) and washed extensively. We performed the
phagocytosis either at 37
 
 
 
C or at 4
 
 
 
C using a 5:1 irradiated tumor
cells (ITCs):phagocyte ratio. After 2 h, we added trypsin-EDTA
at 37
 
 
 
C. We washed M
 
 
 
 monolayers till no residual noninternal-
ized irradiated cells could be detected by phase contrast micros-
copy. In parallel, we separated DCs from noninternalized ITCs
by density gradient centrifugation. We assessed incorporated ra-
dioactivity in a 
 
 
 
-counter after lysis with 1% Triton X-100. The
assay was performed using ITCs incubated in medium containing
either AxV or BSA (final concentration: 100 
 
 
 
g/ml).
We also studied phagocytosis of ITCs by flow cytometry, ac-
cording to the procedure described by Albert et al. (19). In brief,
RMA cells were labeled before irradiation with the aliphatic red
fluorescent dye PKH26-GL (Sigma-Aldrich) and cocultured with
M
 
 
 
 or DCs that had been stained with the green fluorescent
PKH67-GL dye (Sigma-Aldrich). Phagocytosis assays were per-
formed at 37
 
 
 
or 4
 
 
 
C. If indicated, M
 
 
 
 and DCs were preincu-
bated with 2 mM EDTA, 10 
 
 
 
g/ml cytochalasin D, or 40 
 
 
 
M
lavendustin A, respectively. In selected experiments, we assessed
the phagocytosis of AxV-coupled ITCs in the presence of EDTA
or cytochalasin D. 2 h after addition of the apoptotic cells, we
performed flow cytometry analysis and enumerated double posi-
tive cells (20). Phagocytosis percentage was calculated according
to the following formula: (percentage of phagocytosing cells/per-
centage of phagocytosing cells when phagocytes where preincu-
bated in medium) 
 
 
 
 100.
We assayed culture supernatants for TNF-
 
 
 
, IL-1
 
 
 
, IL-10, and
TGF-
 
 
 
 using commercial ELISA (DuoSet ELISA; R&D Systems).
 
In Vivo Clearance of Irradiated Cells.
 
Sterile peritonitis was in-
duced by intraperitoneal injection of 4% thioglycollate. 50 
 
 
 
 10
 
6
 
CFSE-labeled apoptotic cells in 0.5 ml PBS, in the presence or in
the absence of AxV, were injected 5 d after into peritoneal cavi-
ties. After 2 h, mice were killed and peritoneally lavaged with
ice-cold HBSS. Elicited M
 
 
 
 were recovered and analyzed by
flow cytometry after staining with PE-conjugated anti-CD11b
mAb (BD Biosciences).
To evaluate clearance by DCs, 100 
 
 
 
 10
 
6
 
 CFSE-labeled ITCs
in 0.3 ml PBS were injected intravenously. After 90 min, mice
were killed, and spleens were removed. CD11c
 
 
 
 DCs were re-
trieved by magnetic bead sorting with anti-CD11c mAb (Miltenyi
Biotec). Cells were stained with anti-CD3 and anti-B220 Cy-
Chrome–conjugated mAbs and with either PE-conjugated anti-
CD8 or PE-conjugated anti-CD11b mAbs (BD Biosciences).
Cells were analyzed by triple parameter flow cytometry. 
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Immunization and Cure.
 
Mice were s.c. immunized in the
footpad with ITCs (5 
 
 
 
 10
 
6
 
/mouse). ITCs were preincubated ei-
ther with or without chicken AxV and mouse AxV, or physically
coupled to chicken albumin (100 
 
 
 
g/ml) for 20 min at room
temperature. On day 15, we boosted the mice in the right flank.
On day 30, mice were s.c. challenged by injecting 2.5 
 
 
 
 10
 
4
 
 or
5 
 
 
 
 10
 
4
 
 viable RMA cells into the opposite flank. Animals were
checked for the appearance of tumor twice weekly. We scored
animals as tumor positive if the mean of the two perpendicular
diameters of the tumor was 
 
 
 
2 mm and killed them when the
tumor reached a diameter 
 
 
 
10 mm or ulcerated. We scored mice
as tumor negative if no palpable tumor developed within 10 wk
after the tumor challenge. Tumor-free mice were rechallenged
by injecting 2.5 
 
 
 
 10
 
4
 
 RMA cells into the opposite flank to ver-
ify whether the protection was long lasting. We verified the spec-
ificity of the response in protected mice by s.c. administration of
2.5 
 
 
 
 10
 
4
 
 B16F1 melanoma cells.
To evaluate the effect of different treatments on growing
RMA lymphomas, we s.c. injected 2.5 
 
 
 
 10
 
4
 
 living RMA cells
in the left flank. We allowed tumors to grow for 3 d before im-
munization in the opposite flank with 5 
 
 
 
 10
 
6
 
 ITCs treated or
not with AxV (1 immunization/wk for 3 wk). We evaluated tu-
mor growth as described before.
 
Statistical Analysis.
 
Statistical analyses were performed using
either log-rank, two-tailed Student’s 
 
t
 
 test and 
 
 
 
2
 
 (SPSS 10.0.7,
SPSS Inc.; InStat 2.01; GraphPad Software). Results were con-
sidered statistically significant for P 
 
  
 
0.05.
 
Results
 
AxV Specifically Binds to Irradiated RMA Cells.
 
After ir-
radiation, RMA lymphoma cells acquired the ability to
bind FITC-labeled AxV (Fig. 1, A and B). After 16 h,
 
 
 
60% of the cells were AxV positive/propidium iodide
negative and 
 
 
 
30% double positive. The binding of FITC-
labeled AxV was dependent on divalent cations (Fig. 1 C)
and abated when cells were preincubated with unlabeled
AxV (Fig. 1, D and E).
 
AxV Skews the Phagocytosis of Irradiated Cells in Vitro and
In Vivo.
 
We assessed whether interference with PS rec-
ognition influenced the phagocytic clearance of ITCs. To
this aim, we derived thioglycollate-elicited M
 
 
 
 from peri-
toneal lavages or immature DCs from bone marrow pre-
cursors and assessed their ability to phagocytose 
 
125
 
I-conju-
gated or fluorescent ITCs. M
 
 
 
 internalized ITCs at 37
 
 
 
C
more efficiently than DCs (127,475 
 
 
 
 1,246 
 
125
 
I-conju-
gated ITCs/10
 
5
 
 M
 
 
 
 vs. 64,939 
 
 
 
 230/10
 
5
 
 DCs). Further-
more, a larger fraction of M
 
 
 
 were actually involved in
phagocytosis of fluorescent ITCs, as assessed by flow cy-
tometry (71.9 
 
 
 
 3.3% M
 
 
 
 vs. 20.9 
 
 
 
 2.5% DCs). The
process was greatly inhibited when experiments were per-
formed at 4
 
 
 
C (i.e. at a temperature that does not permit
actual phagocytosis) in the presence of cytochalasin D, an
inhibitor of cytoskeletal function or of EDTA, demonstrat-
ing that divalent cations are required (Fig. 2, A and B).
Protein tyrosine kinase integrity is also necessary for inter-
nalization of apoptotic cells by DCs (19); in agreement the
protein tyrosine kinase inhibitor, lavendustin A substan-
tially inhibited phagocytosis of ITCs. AxV inhibited the
uptake of ITCs by M
 
 
 
 (Fig. 2 B). No further significant
inhibition in the uptake of AxV-coupled ITCs occurred in
the presence of EDTA, cytochalasin D, or at 4
 
 
 
C. AxV did
not significantly influence the phagocytosis of ITCs by im-
mature DCs (Fig. 2, D and E).
Thioglycollate-elicited M
 
  challenged with AxV-cou-
pled ITCs secreted significantly higher amounts of TNF- 
(P   0.008) and IL-1  (P   0.036). In contrast, the pro-
duction of TGF-  abated, and the difference was statisti-
cally significant (P   0.040). IL-10 was unaffected. DCs
challenged with ITCs released a similar array of cytokines
in the presence or in the absence of AxV (Fig. 2 C). The
effects of chicken AxV on cytokine production were con-
firmed by experiments using recombinant human AxV. Of
notice, AxV alone did not induce the production of cyto-
kine by both phagocytes (Table I).
Figure 1. AxV specifically binds to irradiated RMA lymphoma cells.
(A) We monitored by flow cytometry the staining with FITC-labeled
annexin V (x axis) and propidium iodide (y axis) of RMA lymphoma cells
at different time points after UV irradiation (0, 3, 9, and 16 h). Percent-
ages are indicated. The experiment shown is representative of four inde-
pendent experiments. (B) We monitored the staining with FITC-labeled
AxV (shaded columns) and propidium iodide (PI, unshaded columns) of
RMA lymphoma cells at different time points after UV irradiation (x axis,
hours). Incubations were performed in the presence of calcium and mag-
nesium. Results are expressed as percentage of positive cells   SD from
four independent experiments (y axis). (C) We monitored the staining
with FITC-labeled AxV (shaded columns) and propidium iodide (PI, un-
shaded columns) of RMA lymphoma cells at different time points after
UV irradiation (x axis, hours) in the absence of divalent cations. Results
are expressed as percentage of positive cells   SD from four independent
experiments (y axis). (D) We treated with increasing amounts of unlabeled
AxV (closed squares) or of BSA (open squares) (x axis concentration, mg/ml)
irradiated lymphoma cells, before assessing the binding of FITC-labeled
AxV. Results are expressed as percentage of positive cells   SD from
three independent experiments (y axis). (E) We treated with unlabeled
AxV (bold lines, 0.05 or 0.25 mg/ml) ITC, before assessing the binding
of FITC-labeled AxV. Thin lines represent the binding of FITC-labeled
AxV to irradiated RMA lymphoma cells in the absence of competitors.
Dotted lines indicate the fluorescence background. The experiment
shown is representative of three independent experiments.Phosphatidylserine Exposure Controls Tumor Immunogenicity 1160
To determine whether AxV was equally effective in
vivo, we challenged animals with CFSE-labeled ITCs in
the presence or in the absence of AxV, and evaluated the
clearance of dying cells by two alternative approaches. First,
we injected fluorescent ITCs into the peritoneal cavity 5 d
after induction of sterile peritonitis with thioglycollate.
Phagocytosis of ITCs by elicited peritoneal M  was im-
paired, and a statistically significant difference in the frac-
tion of engulfing M  was evident in AxV-treated mice af-
ter 2 h (27.9   3.6% vs. 12.6   1.1; P   0.028; Fig. 3, A
Figure 2. AxV skews the phagocytosis of irradiated cells in vitro. (A) We incubated thioglycollate-elicited M  or bone marrow–derived immature
DCs with radioactive irradiated tumor cells (ITC, x axis), at 37 C in the presence (gray columns) or absence (black columns) of AxV. As a control, both
phagocytes were incubated with ITC at 4 C (white columns). Results are representative of seven experiments and expressed as number of engulfed 125I-
conjugated ITC per 105 M  or DC   SD (y axis). Actual cpm per 125I-conjugated ITC was 0.06, and maximum incorporated radioactivity in phagocytes
(at 37 C and in the absence of AxV) was 7654   97 cpm. For other experiments, these values were respectively: 0.01 cpm/cell and 1,021   97 cpm;
0.02 cpm/cell and 9,890   343 cpm; 0.01 cpm/cell and 1,629   6 cpm; 0.02 cpm/cell and 3,489   354 cpm; 0.01 cpm/cell and 1,696   180 cpm; and
0.09 cpm/cell and 539   66 cpm. (B) Peritoneal thioglycollate-elicited M  or bone marrow–derived DCs were stained with the aliphatic PKH67-GL
green fluorochrome and ITC with the aliphatic PKH26-GL red fluorochrome. Phagocytosis was assessed by flow cytometry after 120 min as described in
Materials and Methods. 100% represents the phagocytosis observed when phagocytes were preincubated in culture medium at 37 C (medium). Percent-
age of phagocytosing cells ranged in different experiments from 54.6 to 87.8% for M  and from 16.1 to 24.4% for DCs. Bars refer to the phagocytosis
percentage (calculated as described in Materials and Methods) observed in the presence of AxV, EDTA, lavendustin A (LavA), cytochalasin D (CytoD),
or at 4 C. All results represent mean   SD from at least four experiments. Results obtained were compared with results obtained in medium alone using
two-tailed Student’s t test: *, P   0.01; **, P   0.005; ***, P   0.001. (C) We retrieved the supernatants of peritoneal thioglycollate-elicited M  or bone
marrow–derived DCs challenged for 24 h with ITC coupled (shaded bars) or not (unshaded bars) with AxV (ITC:phagocyte ratio of 5:1). The release of
TNF- , IL-1 , IL-10, and TGF-  was assessed by ELISA as described in Materials and Methods. Results are expressed as ng/ml. Results obtained with
AxV-coupled ITC were compared with results obtained with ITC using two-tailed Student’s t test: *, P   0.01; **, P   0.005. Phagocytosis of ITC by
M  (D) or DC (E) was evaluated by flow cytometry with or without the indicated inhibitors, alone or in combination. Percentages of phagocytosing
cells are indicated. Results shown are representative of at least four independent experiments.Bondanza et al. 1161
and B). This resulted in an actual delay in the clearance of
the apoptotic ITCs from the peritoneum.
Second, we injected fluorescent syngeneic ITCs intrave-
nously and assessed the clearance within the spleen by mag-
netic bead sorting of CD11c  DCs and triple parametric
analysis by flow cytometry. A fraction of CD8 , CD11b 
DCs was consistently engaged in phagocytosis of fluorescent
ITCs and the presence of AxV significantly increased this
value (3.1   0.1% vs. 7.34   2%; P   0.025). We found
that among CD8 , CD11b  splenic DCs only a small per-
centage of cells was actively engaged in phagocytosis, in
both normal and AxV-injected mice (Fig. 3, C and D).
AxV Enhances the Immunogenicity of Irradiated Cells: Vacci-
nation. Mice injected with 2.5   104 living RMA cells
developed the tumor with a mean latency of 13.7   1.9 d
(Fig. 4 A). The s.c. vaccination with ITCs protected the
25% of the animals from tumor growth after the challenge
with living RMA cells (Fig. 4 B). AxV-coupled ITCs were
consistently more efficient vaccines than ITCs alone (Fig. 4
B). 90% of the animals vaccinated with AxV-coupled ITCs
rejected the tumor after the challenge, compared with only
25% of the animals vaccinated with ITCs without AxV
(P   0.0015; Fig. 4 B). Even in the few animals that were
not protected, the latency of tumor appearance and survival
time after tumor development increased. The mean latency
increased from 16.2   3.3 to 23   9.5 for animals treated
with irradiated cells in the absence or in the presence of
AxV (P   0.0064; Fig. 4 B). The mean survival increased
from 24.1   4.9 to 33 d (P   0.0024; Fig. 4 C). Signifi-
cantly enhanced latency and survival were observed when
vaccinated mice were challenged with higher numbers of
living lymphoma cells (Table II); we compared the ability of
AxV of different origins (xenogeneic vs. syngeneic) to
enhance the immunogenicity of ITCs. Both mouse and
chicken AxV associated with ITCs significantly delayed
(from 15   8.3 to 24.1   8 and 27.1   6.2, respectively;
P   0.005) the appearance of the tumor in mice vaccinated
as described before and challenged with 5   104 living
RMA cells. The survival and the protection were signifi-
cantly enhanced as well (P   0.005; Table II). In contrast,
no significant difference in tumor take, animal survival, or
elicited protection was observed between animals treated
with ITCs in the presence of mouse or chicken AxV. More-
over, we failed to increase the immunogenicity of ITCs by
physical coupling with another xenogeneic protein, chicken
ovalbumin (Table II). Altogether, these findings rule out a
bias due to the xenogeneic origin of chicken AxV.
We rechallenged protected mice in the opposite flank
(2.5   104 living RMA cells/animal). In all cases but one,
mice protected by the vaccination with ITCs rejected the tu-
mor (Fig. 4 B). We challenged protected animals with an un-
related tumor, the B16F1 melanoma. All mice developed the
melanoma, with a latency and a survival identical to nonim-
munized mice (unpublished data). Therefore, the response we
elicited was long lasting, endowed with memory and specific.
AxV Enhances the Immunogenicity of Irradiated Cells: Cure
of Growing Tumors. We injected naive mice with 2.5  
104 viable RMA cells. We allowed a 3-d period for the tu-
mor to develop before injection of ITCs, coupled or not
with AxV. The tumor did not grow in the 10% of the ani-
mals treated with ITCs alone (Fig. 4 D). In contrast, 60% of
the mice treated with AxV-coupled ITCs were cured (Fig.
4 H). The result was statistically significant (P   0.019).
Discussion
Scavenger cells recognize exposed moieties on dying
cells. The outcome is the swift phagocytosis of the corpses,
Table I. AxV Biases towards Inflammation the Phagocytic Clearance of ITCs
Macrophages Dendritic cells
Medium AxV Medium AxV
Cytokines Alone w/ ITC Alone w/ ITC Alone w/ ITC Alone w/ ITC
pg/ml pg/ml pg/ml pg/ml pg/ml pg/ml pg/ml pg/ml
TNF-  125   15 335   30 117   24 978   48a 267   137 392   79 245   121 426   78
IL-1  21   5 44   7 14   1 322   85b 10   4 46   48    3 47   3
IL-10 88   18 105   30 129   11 90   8 42   1 51   8 42   2 43   4
TGF-  82   10 505   54 105   11 193   26b 230   72 266   76 238   93 261   65
We retrieved the supernatants of thioglycollate-elicited peritoneal M  or bone marrow–derived DCs challenged for 24 h with ITC coupled or not
(medium) with chicken AxV (ITC:phagocyte ratio of 5:1). The supernatants were also retrieved from cells incubated for 24 h in medium (alone)
with or without chicken AxV. The release of TNF- , IL-1 , IL-10, and TGF-  was assessed by ELISA as described in the Materials and Methods.
Results are expressed as pg/ml (mean   SD). Results obtained with AxV-coupled ITC were compared with results obtained with ITC using two-
tailed Student’s t test.
aP   0.005.
bP   0.01.Phosphatidylserine Exposure Controls Tumor Immunogenicity 1162
which prevents secondary necrosis and the ensuing tissue
damage. The recognition of exposed PS via its receptor (9)
triggers the release of immunosuppressive cytokines, in par-
ticular TGF- , which quench inflammation and prevent
the maturation of antigen-presenting DCs. Tolerance in-
duction is the likely default outcome (21, 22). The events
recruited by the recognition of exposed PS residues, in-
cluding the release of immunosuppressive cytokines, possi-
bly contribute to the tolerogenic outcome (23). However,
environmental signals, including signals recruiting the CD40
receptor (24), delivered by local cytokines, or possibly re-
leased by the dying cells themselves (25, 26), switch the re-
sponse toward active cross-priming (3).
Dying tumor cells represent a source of antigens for active
antineoplastic immunotherapy. Antigen-presenting DCs ef-
ficiently phagocytose dying tumor cells and prime immune
responses against tumor antigens both in vitro and, in suit-
able conditions, in vivo. However, this is not the rule in
vivo. We reasoned that disrupting the local PS-dependent
clearance of dying cells by M  would result in “unscav-
enged” dead tumor cells, available for uptake and processing
by DCs. Indeed, we confirmed that the PS-binding protein
AxV is a suitable tool to obtain this proof of concept because
it interferes with the in vitro clearance of dying ITCs by
M , consistent with previous observations (8, 12–14).
The engulfment of apoptotic cells is a two-step process.
The first involves binding without actual internalization.
Ingestion of cell corpses is the second step (27). Several re-
ceptors, including CD14, CD36, and  v integrins, are in-
volved in the recognition of apoptotic cells (“tethering”
receptors). However, the ingestion by macropinocytosis
requires recognition of PS on the membranes of the apop-
Figure 3. AxV skews the phagocytosis of irradiated cells in vivo. (A) The
in vivo clearance of CFSE-labeled fluorescent ITC by elicited CD11b 
M  in the absence (w/o AxV) or in the presence (w AxV) of AxV was
evaluated by flow cytometry. (B) The percentage of phagocytosing M 
(mean of three independent experiments   SD), in the absence (w/o,
unshaded bar) or in the presence (w, shaded bar) of AxV is shown. The
difference was statistically significant. *, P   0.05. (C) The clearance of
i.v. injected CFSE-labeled ITC by splenic DCs was evaluated by flow cy-
tometry. CD11c  DCs were retrieved by magnetic bead sorting (purity
 95%). CD11b , CD8  DCs (top) and CD11b , CD8  DCs (bottom)
phagocytosing ITC in the absence (w/o AxV) or in the presence of AxV
(w AxV) were identified by triple parameter flow cytometry. (D) The
percentage of phagocytosing CD11b , CD8  (CD8 , top histograms)
and CD11b , CD8  (CD8 , bottom histograms) DCs in the absence (w/o,
unshaded bars) or in the presence (w, shaded bars) of AxV in two inde-
pendent experiments is shown (exps. 1 and 2).
Figure 4. AxV-coupled ITC protect and cure mice from lethal tumor
challenge and determine long-lasting antitumor immunity. C57Bl/6 mice
were immunized twice with PBS (A) or ITC (B) in the presence (closed
triangles) or not (open triangles) of AxV (see Materials and Methods). On
day 0, we challenged immunized mice s.c. in the opposite flank with
2.5   104 viable RMA lymphoma cells and we monitored at different
times (x axis, days) the percentage of tumor-free animals (y axis). To eval-
uate whether the elicited response was long lasting, we rechallenged pro-
tected animals on day 72 with 2.5   104 viable RMA lymphoma cells
(arrow). (C) Days elapsing before tumors appearance (y axis, latency) and
the survival time (y axis, survival) in vaccinated animals that were not
protected (see Materials and Methods). Each symbol refers to a single
mouse; only mice developing the tumor are depicted. Statistical analysis
was performed with the  2 test, choosing as cut-off 18 d for the latency
and 28 d for the survival, comparing the results obtained in all treated an-
imals in four independent experiments. 25 mice were vaccinated with
PBS, 18 mice were vaccinated with AxV, 17 mice were vaccinated with
ITC alone, and 22 mice were vaccinated with ITC   AxV. *, P   0.01;
**, P   0.005; ***, P   0.001. (D) We injected 2.5   104 living RMA
cells s.c. in the left flank of C57Bl/6 mice. On day 4, ITC were injected
into the opposite flank alone (open symbols) or in the presence of AxV
(closed symbols). The percentage of tumor free animals (y axis) was evalu-
ated at different time points after treatment (x axis, days). Differences were
statistically significant, as ascertained by log-rank test (for the vaccination
experiments, P   0.0015; for the cure experiments, P   0.019).Bondanza et al. 1163
totic cells (28). Our results fit well with this model. AxV
efficiently binds to exposed PS. Without the PS “tickle”
signal, which is necessary for the reorganization of the ac-
tin-based cytoskeleton upon activation of Rho GTPases
(27), M  internalization fails. PS recognition also elicits the
release of immunosuppressive cytokines, namely TGF- 
(29), and we found that thioglycollate-elicited M  clearing
ITCs in the presence of AxV secreted a significantly lower
amount of TGF-  and higher amounts of IL-1  and TNF- 
(Table I).
Somersan and Bhardwaj predicted that immature DCs,
which are highly macropinocytic and express the constitu-
tively activated Rho GTPase Cdc42, would be less depen-
dent than M  on tickling signals to internalize tethered ap-
optotic cells (30). Our results are in agreement with this
prediction: AxV, which hinders PS-elicited internalization
of apoptotic cells, but not their “tethering” via CD36 and
the  v integrin (1, 2), did not influence phagocytosis by
DCs (Fig. 2). Actually, possibly due to the decreased in
vivo clearance by elicited M  (Fig. 3, A and B), splenic
CD11c  DCs phagocytosed more efficiently ITCs injected
in the presence of AxV (Fig. 3, C and D). Of importance,
the clearance by DCs both in the presence or in the ab-
sence of AxV was restricted in vivo to CD8  DCs (Fig. 3,
C and D). This is an agreement with papers that implicate
CD8  DCs in the cross-presentation of cell-associated anti-
gens (31–36). Accordingly, AxV significantly increased the
fraction of CD8  DCs that phagocytose ITCs, but did not
influence the phagocytosis by CD8  DCs (Fig. 3). The
molecular basis of the different ability of M , CD8 , and
CD8  DCs to phagocytose dying cells is the object of in-
tense investigation. However, it has been suggested that
CD8  DCs selectively express a receptor for apoptotic cells
(33, 37). Our results suggest that recognition via this yet
unidentified moiety is not affected by the two-dimensional
crystalline lattice AxV forms on membrane phospholipids.
CD8  DCs participate in both cell priming and cell tol-
erance to cell-associated antigens (38–42). The factors dic-
tating the outcome of cross-presentation include microbial
products and endogenous proinflammatory signals, which
convert a tolerogenic response by CD8  DCs into produc-
tive immunity (40). In our case, endogenous factors possi-
bly released as a consequence of delayed clearance by scav-
enger phagocytes are likely to be involved (43).
In agreement, the administration of AxV-coupled ITCs
into naive animals protected them from the challenge with
living lymphoma cells. The protection we achieved was
long lasting and specific. AxV-coupled cells were signifi-
cantly more immunogenic than their untreated counter-
parts (Fig. 4). This number of cells proved highly efficient
in causing the rejection of tumors already growing in vivo.
The result required the presence of AxV, with statistically
significant difference in the latency with which the tumor
appeared, in the survival of vaccinated mice and in the
number of protected mice (Fig. 4).
Immunity does not spontaneously initiate when tissue
cells die by necrosis and release autoantigens and intracellu-
lar adjuvants (25). This highlights a role for immunoregula-
tory activities recruited at the site of dying cell clearance.
Scavenger M  releasing immunosuppressive cytokines are
possibly involved. Intriguingly, the failure in the function
of M  is involved in the pathogenesis of the prototypic au-
toimmune disease systemic lupus erythematosus, and the
defective clearance of dead cells associates to persistent au-
toimmunity in vivo (7, 44, 45).
Tumor-associated antigens, contained in dying cells, can
elicit immune responses. However, they normally fail to do
so. Identical constraints are likely to restrict the onset of
noxious autoimmune responses and protective tumor-spe-
cific immunity (46). We increased the immunogenicity of
dying tumor cells by interfering with the PS-dependent
recognition (47) and immunosuppressive clearance of dy-
ing cells, a mechanism involved in the physiological main-
tenance of peripheral tolerance.
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Table II. AxV Increases the Immunogenicity of ITCs
Take Survival Protection
PBS 9.3   1.9 14.2   1.9 0/10
mAxV 8.2   1.6 13.8   2 0/4
cAxV 7.6   1.3 12.4   1.7 0/4
cOVA 11   2.6 15.8   2.8 0/4
ITC 15   8.3 16.8   7 2/10
ITC   mAxV 24.1a   8 26.1a   5.3 6/10a
ITC   cAxV 27.1a   6.2 28a   4.2 6/10a
ITCbiot 19.8   6.1 24   3.7 1/4
ITCbiot   cOVA 18.6   8.2 22.3   5.9 3/10
Results are expressed as the tumor take (days elapsing between the
challenge with living tumor cells and the appearance of the lymphoma
in vivo; mean   SD), the survival (days elapsing between the challenge
with living tumor cells and the death; mean   SD), and the elicited
protection (number of protected animals/number of vaccinated animals)
of mice vaccinated with saline, living, and apoptotic melanoma cells,
alone or coupled with AxV of mouse (mAxV) or chicken (cAxV) origin.
As a further negative control, ITC were biotinylated and used as an
immunogen, coupled or not with another irrelevant xenogeneic protein
(chicken ovalbumin [cOVA]). 
aP    0.005, significantly different from ITC alone and ITCbiot   
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J.R. Kalden holds a patent on the use of AxV as adjuvant for apop-
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inventors. M. Herrmann is a partner of a company that owns a li-
cense of this patent.
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